title: Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy.
abstract: BACKGROUND
  Troponin T (TnT) is valuable for short- and long-term risk stratification of patients with acute coronary syndromes (ACS). It also may predict which ACS patients will benefit from glycoprotein (GP) IIb/IIIa blockade.
  
  
  RESULTS
  We prospectively studied 1160 patients with non-ST-segment elevation ACS randomized in PARAGON-B to receive lamifiban, an intravenous GP IIb/IIIa antagonist, or placebo. TnT levels were obtained before study treatment began and 24 to 72 hours later; assays were performed by a blinded core laboratory. At baseline, 40.2% of patients were TnT-positive (>/=0.1 ng/mL); these patients were older and more often male or smokers. Patients positive at baseline had a significantly higher rate of the primary end point (composite of death, myocardial [re]infarction, or severe recurrent ischemia at 30 days; odds ratio, 1.5; 95% CI, 1.1 to 2.1) than those who were TnT-negative. Lamifiban was associated with significant reduction in the primary end point (from 19.4% to 11.0%, P=0.01) among TnT-positive patients but not among TnT-negative patients (11.2% for placebo versus 10.8% for lamifiban, P=0.86; P=0.08 for test of interaction between TnT status and treatment assignment). This pattern held for the end points of death alone and death or myocardial (re)infarction at 30 days. Peak TnT level at 48 hours did not differ with lamifiban treatment.
  
  
  CONCLUSIONS
  TnT predicts poor short-term outcomes in non-ST-segment elevation ACS. Treatment benefit with lamifiban is limited almost exclusively to TnT-positive patients, reducing 30-day adverse outcomes to a rate nearly identical to that of negative patients.
authors: Duke Clinical Research Institute, Durham, NC, USA. newby001@mc.duke.edu
authors: L K
authors: LK
authors: Newby
authors: E M
authors: EM
authors: Ohman
authors: R H
authors: RH
authors: Christenson
authors: D J
authors: DJ
authors: Moliterno
authors: R A
authors: RA
authors: Harrington
authors: H D
authors: HD
authors: White
authors: P W
authors: PW
authors: Armstrong
authors: F
authors: F
authors: Van De Werf
authors: M
authors: M
authors: Pfisterer
authors: V
authors: V
authors: Hasselblad
authors: R M
authors: RM
authors: Califf
authors: E J
authors: EJ
authors: Topol
mesh_terms: D000085:Acetates / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D000208:Acute Disease; D000368:Aged; D003327:Coronary Disease / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D004311:Double-Blind Method; D004562:Electrocardiography; D023381:Endpoint Determination; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D011446:Prospective Studies; D055502:Secondary Prevention; D015996:Survival Rate; D016896:Treatment Outcome; D020107:Troponin T / Q000097:blood*; D014443:Tyrosine / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood
chemical_list: D000085:Acetates; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D020107:Troponin T; D014443:Tyrosine; C084062:lamifiban